Pharming Group (NASDAQ:PHAR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02), Zacks reports. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Pharming Group updated its FY 2025 guidance to EPS.
Pharming Group Trading Up 14.5 %
Shares of PHAR stock traded up $1.12 during trading hours on Thursday, hitting $8.86. 9,496 shares of the company were exchanged, compared to its average volume of 6,128. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.80. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The firm has a fifty day moving average of $9.05 and a 200 day moving average of $8.57. The firm has a market cap of $602.75 million, a PE ratio of -34.08 and a beta of -0.10.
Analysts Set New Price Targets
PHAR has been the topic of several research analyst reports. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $37.00 target price on shares of Pharming Group in a report on Tuesday, December 17th.
Get Our Latest Report on PHAR
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
